BrainStorm Therapeutics, Inc.
Robert T. F. is an accomplished biopharmaceutical leader with extensive experience in neuroscience and drug discovery. Currently serving as the Founder and CEO/CSO of BrainStorm Therapeutics, Inc. since March 2023, Robert focuses on developing breakthrough medicines for central nervous system disorders using innovative drug discovery methods. Previously, as Chief Scientific Officer at Vyant Bio, Robert spearheaded a significant transition towards a drug discovery platform, advancing a clinical candidate for Rett syndrome to a Phase 2 trial. Robert's notable roles also include Executive Director at CAMP4 Therapeutics, Vice President of Research and Development at AegisCN LLC, and Chief Scientific Officer at Rapid Pharma/Resolute Bio, Inc. Additionally, Robert has held significant academic positions at the University of California, San Francisco, and Duke University Medical Center, contributing to essential discoveries in neurotransmitter systems. Robert holds a PhD in Biochemistry from The George Washington University and completed postdoctoral training in Molecular Neuroscience at Columbia University.
This person is not in any teams
BrainStorm Therapeutics, Inc.
BrainStorm Therapeutics is developing an all-in-human brain organoid platform that integrates experimental and computational approaches to discover disease-modifying therapies for brain disorders. We engineer brain organoids with mutations known to drive disease and probe them with high-throughput screens to develop AI-driven digital organoid foundation models to identify and validate therapeutic targets and drug candidates that reverse disease progression. Our founding team successfully identified a therapeutic candidate for the rare genetic neurodevelopmental disorder, Rett syndrome, advancing to a Phase 2 clinical trial by screening patient-derived cortical brain organoids. Our first therapeutic programs are focused on rare genetic neurodevelopmental disorders and diseases caused by degeneration or dysfunction of midbrain dopamine neurons, including Parkinson’s disease, schizophrenia, and addiction. Our highly scalable platform can address other complex brain disorders and therapeutic areas.